Clin2
NCT05049603Possibly a fitNot yet recruiting

Atorvastatin for active moderate to severe Graves’ eye disease

Graves' Orbitopathy

Treatments studied

Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.

This trial tests whether atorvastatin (a cholesterol-lowering pill) can improve active, moderate-to-severe Graves’ orbitopathy (eye swelling and bulging). It compares outcomes in people who meet specific safety and disease-activity requirements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
102 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have Graves’ disease and your thyroid levels are controlled (euthyroid) on stable treatment
  • Your eye condition is moderate-to-severe, with signs like eye bulging, double vision, or eyelid retraction
  • Your Graves’ eye disease is active right now (your doctor measures an activity score of 3 or higher)
  • You’re able to give written consent and attend regular follow-up visits
  • Blood tests are safe: liver enzymes and CPK are no more than 3 times the normal upper limit
  • You can meet pregnancy prevention rules if you can become pregnant, and avoid certain medicines before/during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07762105Not yet recruiting· Phase 1
Atorvastatin for moderate-to-severe thyroid eye disease

This study tests whether the cholesterol-lowering drug atorvastatin can help people with active, moderate-to-severe thyroid eye disease (swelling and bulging of the eyes caused by an overactive thyroid). You will receive the drug or a placebo alongside your usual steroid treatment, and your eyes will be checked over about a year.

Yogyakarta, Yogyakarta, Indonesia
NCT07547930Recruiting· Phase 2
Tofacitinib for Steroid-Resistant Thyroid Eye Disease

This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.

Xiamen, Fujian
NCT03131726Recruiting· Phase 3
Simvastatin for Graves eye disease in mild-to-moderate cases

This trial tests whether simvastatin (a cholesterol medicine) can improve eye symptoms from Graves’ eye disease. It is aimed at people with active mild-to-moderate disease and will also check safety with blood tests, heart/skin tolerance, and stomach health.

Malmö
NCT03098225Not yet recruiting· Phase 4
Orbital radiation for active Graves eye disease

This trial tests whether orbital (eye-socket) radiotherapy can improve active Graves’ orbitopathy, a condition that affects the eyes and eye muscles. It may help reduce eye inflammation and related symptoms if you meet the specific activity and severity criteria.

NCT06693856Enrolling by invitation
Steroid pulse therapy for active Graves' eye disease

This study tests whether high-dose steroid pulses (given through a vein) can help people with moderate to severe Graves' eye disease that is still active. It is for people who have not yet been treated with steroids and whose eye problems began within the past year.

Shanghai, Shanghai Municipality
NCT05126147Recruiting· Phase 4
Hydroxychloroquine for mild Graves’ eye swelling

This trial studies whether hydroxychloroquine can improve mild Graves’ orbitopathy (swelling and discomfort around the eyes). It’s meant for people with mild symptoms and who haven’t recently used certain eye or immune treatments.

Hsinchu

Hear when a new Graves Orbitopathy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.